Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625060 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
A Phase 2 study of Chronic Migraine and Episodic Migraine, sponsored by Ipsen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 641
- Enrollment target
- 20
- Study locations
NCT06625060 is a Phase 2 study of Chronic Migraine and Episodic Migraine that is actively recruiting participants, run by Ipsen. The registered enrollment target is 641 participants, above the 306-participant average among 17 other Chronic Migraine trials with a reported enrollment target (109% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06625060, a Phase 2 study of Chronic Migraine and Episodic Migraine, is actively recruiting participants, sponsored by Ipsen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 641 participants
- Enrollment target
- 20
- Study locations
Study Summary
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics. This study aims to determine: * The safety and efficacy of injecting IPN10200 directly into the muscles of the head and neck to prevent EM and CM, * The right amount (dose) of IPN10200 to inject at each point, * The total amount (dose) of IPN10200 that provides the best balance between safety and efficacy preventing migraines. Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL IPN10200
- BIOLOGICAL IPN10200 dose A
- BIOLOGICAL IPN10200 dose B
Study Locations (20)
California
- Axiom Research, LLC - Apple Valley
- Profound Research. LLC - NCSC - Carlsbad
- M3Wake -PRI Encino - Encino
- WR-PRI Encino - Encino
- Neuro-Pain Medical Center - Fresno
- Fullerton Neurological Center - Neurology - Fullerton
- Neurology Center of North Orange County - Fullerton
- University of California, Irvine - Department of Neurology - Irvine
- Kaizen Brain Center - La Jolla
- Pharmacology Research Institute (PRI) - Los Alamitos
- Pharmacology Research Institute (PRI) - Los Alamitos/Long Beach - Newport Beach
- Profound Research, LLC - Pasadena
- Acclaim Clinical Research - Internal Medicine - San Diego
- Clinical Trials Management LLC - Thousand Oaks
- Alliance Clinical West Hills (Focus Clinical Research) - West Hills
Alabama
- Central Research Associates - Birmingham
- Rehabilitation & Neurological Services, LLC - Huntsville
Arizona
- MD First Research - Chandler - Neurology - Chandler
- MD First Research - Chandler - Chandler
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2027-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06625060
The ClinicalTrials.gov registry entry for NCT06625060 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 641 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 306-participant average among 17 other Chronic Migraine trials with a reported enrollment target (109% higher). The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Migraine appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06625060 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06625060 about?
NCT06625060 is a clinical study titled "A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults". A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which ...
What is the current status of trial NCT06625060?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 641 participants. The study started on 2024-10-10. Estimated completion is 2027-06-15.
What conditions does trial NCT06625060 study?
This clinical trial studies the following conditions: Chronic Migraine, Episodic Migraine.
What interventions are being tested in trial NCT06625060?
The interventions under investigation include: Placebo (OTHER), IPN10200 (BIOLOGICAL), IPN10200 dose A (BIOLOGICAL), IPN10200 dose B (BIOLOGICAL).
Who is sponsoring clinical trial NCT06625060?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625060 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BOTOX® vs. XEOMIN® for Chronic Migraine
RECRUITING · Phase 3
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
RECRUITING
-
Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)
RECRUITING · NA
-
Acceptance and Commitment Therapy to Improve Disability in Chronic Migraine
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.